Abstract
Objective
To determine the cost to the NHS and the impact on anxiety of a one stop clinic for assessing women with suspected breast cancer.
Study design
Randomised controlled trial.
Participants
Women aged 35 or over referred with a breast lump.
Study setting
Teaching hospital, north west England.
Interventions
Women were randomly allocated to attend a one stop clinic or a dedicated breast clinic.
Outcome measures
Reduction in mean anxiety from baseline at 24 hours after the first visit and at 3 weeks and 3 months after diagnosis; mean cost per patient.
Results
670 women were randomised. Compared with women who attended the dedicated clinic, patients attending the one stop clinic were less anxious 24 hours after the visit (adjusted mean change in state anxiety −5.7 (95% confidence interval −8.4 to −3.0)) but not at 3 weeks or 3 months after diagnosis. The additional cost to the NHS of a one stop attendance was £32 per woman; this was largely explained by greater cytopathological and radiological staff costs.
Conclusion
One stop clinics may not be justified in terms of a reduction in short term anxiety.
What is already known on this topic
One stop clinics have been set up for a wide range of conditions
Rapid alleviation of anxiety has been observed in women attending a one stop clinic for assessing breast problems
The additional costs of providing this service have not been adequately quantified
What this study adds
The benefits of one stop clinics are, in the main, short term
The costs saved by the reduction in the frequency of outpatient visits are more than offset by those associated with same day reporting of diagnostic tests
Introduction
Women with suspected breast cancer should be assessed in a dedicated clinic offering imaging and fine needle aspiration cytology at the initial visit.1 One stop clinics that offer same day reporting of diagnostic investigations further reduce delay.2–4 These clinics are assumed to be more cost effective because prediagnostic visits are reduced, but the consequences for other hospital services have not been quantified. One stop clinics must be provided by consultants because women are seen only once,5 throughput will be less because more time is needed to discuss findings and management, and consultant radiologists and pathologists who usually batch report investigations must be available for the whole clinic although not always needed. Although prolonged investigations can reinforce patients' concerns,6,7 the anxiety of women with symptomatic benign breast disease cannot always be allayed, and the additional benefit of further foreshortening the diagnostic process should be measured.2,8 We report a randomised controlled trial comparing the costs and benefits of a one stop policy for women with suspected cancer with those of a dedicated breast clinic.
Methods
Participants and interventions
Of 70 new appointments scheduled weekly in a dedicated clinic at Withington Hospital, Manchester, 20 were for urgent assessment of women aged 35 or over with a breast lump. Between April 1995 and November 1996, appointment clerks used a balanced block design stratified by consultant and generated by an independent statistician to randomly allocate these women an appointment in a dedicated breast clinic or a one stop clinic. Non-attenders were re-randomised. Recruitment was suspended for six months because of staff shortages. A randomised consent design was used, and women were randomised before consent was obtained. All women were sent information outlining the study. Women allocated to a one stop clinic were informed that they had been randomly selected to attend a new clinic but could opt for the usual clinic. Before assessment, a researcher discussed the trial with women in both groups; those not wishing to participate could still keep their scheduled appointment, and women allocated to a one stop clinic again had the option to change. Participants gave written consent.
Women attending a one stop clinic had a mammogram in the screening assessment unit, after which a consultant radiologist could perform ultrasonography. A consultant surgeon assessed patients when imaging reports were available. Women undergoing aspiration cytology waited while this was reviewed by the consultant pathologist. The surgeon then reassessed patients and discussed their management. Women attending a dedicated clinic were first assessed by a surgeon; if further investigations were undertaken, women were asked to return the following week to discuss the results.
We abstracted activity data from case notes at diagnosis and 12 months later and used the cancer registry to identify cases of breast cancer diagnosed elsewhere during follow up. We measured psychological distress by using the state scale of the state-trait anxiety inventory and the anxiety subscale of the hospital anxiety depression scale.9,10 Women completed questionnaires immediately before assessment (baseline), 24 hours after the first visit (state scale), and three weeks and three months after diagnosis (anxiety subscale). The local research ethics committee approved the study.
Economic evaluation
We set costs from an NHS perspective. We obtained costs of staff and investigation for the first visit and follow up visits, including 40% overheads, from South Manchester University Hospitals Trust (1998). The costs of setting up the clinic and of treatment were excluded, as were the costs of investigations that were undertaken in less than 1% of patients. We aggregated costs for each group and derived a mean cost per patient. Sixty new referrals, including 10 trial participants, were seen in the dedicated breast clinic staffed by two consultants, two senior registrars, and two registrars; each patient was allocated 18 minutes of surgical time. The remaining 10 trial participants seen in the one stop clinic were each allocated 21 minutes of consultant surgical time. We apportioned costs to reflect the grade of the surgeon undertaking the initial assessment. Nursing costs reflect the number and grade of staff rostered for each clinic. One stop clinic costs include two hours of a consultant radiologist's time because it takes 10-15 minutes to obtain and report a mammogram. A consultant pathologist and a grade 3 laboratory technician were available for the whole one stop clinic but afterwards agreed that half their time was spent on other activities while awaiting specimens, and costs were thus based on 1.75 hours of dedicated time. In the one stop clinic, initiation of investigations, transport of specimens, and retrieval of test results were expedited outwith usual services, and these costs were included in the analysis.
After initial assessment, all further visits were to a dedicated follow up clinic, irrespective of where initial assessment took place; we estimated the mean staff costs of these visits by dividing costs for each session by the average number of appointments. In the one stop clinic, the radiologist performed ultrasonography while awaiting the next set of mammograms, and we have therefore excluded operator costs. We similarly adjusted cytology costs to avoid double counting of pathology staff time.
Sample size
In a pilot study, 33% of women in a one stop clinic were anxious (score >7) three weeks after diagnosis. Assuming a control rate of 48%, 460 women were needed to detect a 15% difference between groups for 90% study power at the 5% two sided significance level. Achieving this target sample size required randomisation of 757 women, assuming that 90% would attend and that 90% of attenders would participate, with 75% of participants completing follow up questionnaires. The study period was extended because of cancelled clinics and two unexpected sources of attrition: researchers failed to identify all women before assessment, and some women were found to be ineligible. Based on our original prevalence estimates, we set a termination date to achieve 80% power. The study had 79% power to exclude a 15% difference.
Statistical analysis
We adopted an intention to treat approach and analysed patients in their assigned groups11,12; all participants contributed to the economic evaluation, but only those completing questionnaires at baseline and the time point of interest contributed to the analyses of anxiety. We used analysis of covariance to examine changes in mean anxiety score from baseline, with baseline as the covariate,13 and Stata 6.0 to construct bootstrap 95% confidence intervals for the difference in mean cost.
Results
Six hundred and ninety five appointments were offered to 670 women, of whom 633 (94.5%) attended. We subsequently excluded 94 women—69 (10.9%) not interviewed before assessment, 19 (3.0%) found to be ineligible, and 6 (0.9%) with reading difficulties (fig). Sixty one (11.3%) of 539 remaining women declined to participate; these were more likely to have been allocated to the dedicated clinic (15% v 8% (χ2=5.29, df=1, P=0.021)), to have cancer (30% v 13% (χ2=9.68, df=1, P=0.002)), and to be older (mean age 56 v 49 years (t=4.91, df=537, P<0.0001)). The final study population comprised 478 women—267 (55.9%) randomised to a one stop clinic and 211 (44.1%) randomised to a dedicated breast clinic. Baseline characteristics were similar across groups (table 1).
Table 1.
Baseline characteristics of 478 participating women. Values are numbers (percentages) unless stated otherwise
Baseline characteristics | One stop clinic (n=267) | Dedicated breast clinic (n=211) |
---|---|---|
Age (years): | ||
Mean (SD) | 50 (10.5) | 49 (10.5) |
Range | 35-86 | 35-95 |
Family history of breast cancer: | ||
Yes | 58 (23.4) | 36 (19.1) |
No | 190 (76.6) | 152 (80.9) |
Missing | 19 | 23 |
Menopausal status: | ||
Premenopausal or perimenopausal | 143 (57.4) | 123 (62.1) |
Postmenopausal | 106 (42.6) | 75 (37.9) |
Missing | 18 | 13 |
Presenting symptoms: | ||
Lump in left breast | 124 (46.4) | 106 (50.2) |
Lump in right breast | 128 (47.9) | 95 (45.0) |
Bilateral lump | 3 (1.1) | 2 (0.9) |
Other | 12 (4.5) | 8 (3.8) |
Time lapse (days) between referral and attendance: | ||
Median (range) | 14 (0-105) | 14 (0-50) |
Missing | 11 | 2 |
Initial assessment under care of: | ||
Consultant A | 115 (43.1) | 79 (37.4) |
Consultant B | 152 (56.9) | 132 (62.6) |
Psychological morbidity | ||
State-trait anxiety scale: | ||
Mean (SD) trait score | 39.6 (10.6) | 37.9 (10.0) |
Missing | 13 | 16 |
Mean (SD) state score | 48.4 (14.0) | 47.6 (14.8) |
Missing | 8 | 14 |
Hospital anxiety and depression scale: | ||
Anxiety subscale | ||
not anxious | 110 (41.5) | 88 (41.7) |
anxious | 155 (58.5) | 123 (58.3) |
mean (SD) anxiety score | 9.1 (4.5) | 9.1 (4.8) |
missing | 2 | 0 |
Depression subscale | ||
mean (SD) depression score | 4.0 (3.5) | 3.9 (3.4) |
missing | 2 | 0 |
Clinical activity
Table 2 shows results for clinical activity. Patients seen in a one stop clinic were more likely to be assessed initially by a consultant or a senior registrar (94.8% v 62.1%, difference=32.7% (95% confidence interval 25.6% to 39.7%)), to have mammography (97.8% v 83.4%, 14.4% (9.2% to 20.1%)) or ultrasonography (88.4% v 17.5%, 70.9% (63.7% to 76.5%)) at diagnosis, and to be given a diagnosis at first visit (91.0% v 49.3%, 41.7% (33.9% to 49.0%)).
Table 2.
Clinical activity. Values are numbers (percentages) unless stated otherwise
One stop clinic (n=267) | Dedicated breast clinic (n=211) | Significance | |
---|---|---|---|
Median No (range) of days between first attendance and diagnosis | 0 (0-85) | 8‡ (0-190) | Z=11.67, P<0.0001 |
Visits before diagnosis made: | |||
One visit | 243 (91.0) | 104 (49.3) | |
Two visits | 19 (7.1) | 78 (37.0) | Z=10.12, P<0.0001 |
Three or more visits | 5 (1.9) | 29 (13.7) | |
Women who were assessed by consultant or senior registrar | 253 (94.8) | 131 (62.1) | χ2=77.58, df=1, P<0.0001 |
Women undergoing a diagnostic procedure: | |||
Mammography* | 261 (97.8) | 176 (83.4) | χ2=29.11, df=1, P<0.0001 |
Ultrasonography | 236 (88.4) | 37 (17.5) | χ2=238.7, df=1, P<0.0001 |
Fine needle aspiration cytology† | 124 (46.4) | 92 (43.6) | χ2=0.28, df=1, P=0.6 |
Core biopsy | 12 ( 4.5) | 9 (4.3) | χ2=0, df=1, P=1 |
Aspiration of cyst | 61 (22.8) | 55 (26.1) | χ2=0.5, df=1, P=0.48 |
Excision biopsy | 14 (5.2) | 9 (4.3) | χ2=0.08, df=1, P=0.78 |
Women diagnosed as having: | |||
No abnormality detected | 40 (15.0) | 49 (23.2) | |
Benign lump | 83 (31.1) | 65 (30.8) | |
Cyst | 81 (30.3) | 55 (26.1) | χ2=6.91, df=5, P=0.23 |
Other benign condition | 20 (7.5) | 16 (7.6) | |
Ductal carcinoma in situ or atypical | 4 (1.5) | 1 (0.5) | |
Cancer | 39 (14.6) | 25 (11.8) | |
Mean No of visits after diagnosis | 1.18 | 1.05 | Z=0.78, P=0.44 |
Differences between study groups were analysed by using χ2 test with a continuity correction for categorical data and Mann-Whitney test with normal approximation for other data.
4 dedicated breast clinic patients had mammography repeated.
6 one stop clinic patients and 14 dedicated breast clinic patients had aspiration cytology repeated.
8 days is the time from first assessment to next available follow up visit.
Anxiety
In both groups, mean anxiety scores at all time points were lower than at baseline (table 3). Reduction in mean anxiety was significantly greater for one stop clinic patients at 24 hours (differenceadj=−5.7 (−8.4 to −3.0)) but not at three weeks (−0.2 (−1.0 to 0.5)) or three months (−0.5 (−1.3 to 0.3)). At three weeks, 41.8% (n=87) of one stop clinic patients and 48.4% (74) of dedicated clinic patients were anxious (score >7); the equivalent figures at three months were 42.7% (94) and 47.5% (75). In both groups, baseline scores were similar in women completing and not completing follow up questionnaires.
Table 3.
Change from baseline in mean anxiety scores. Values are mean (SD) unless stated otherwise
One stop clinic | Dedicated breast clinic | Test of significance | P value | |
---|---|---|---|---|
State anxiety score: | ||||
Baseline | 48.1 (13.9) | 47.2 (14.9) | ||
24 hours | 34.5 (14.6) | 39.8 (15.8) | F1,389=17.27 | P<0.0001 |
Hospital anxiety and depression scale anxiety score: | ||||
Baseline | 8.9 (4.4) | 8.8 (4.9) | ||
Three weeks | 7.3 (4.7) | 7.4 (4.3) | F1,358=0.35 | P=0.55 |
Baseline | 8.9 (4.4) | 9.0 (5.0) | ||
Three months | 7.0 (4.6) | 7.5 (4.7) | F1,375=1.51 | P=0.22 |
State anxiety scores: n=392 (220 in one stop clinic and 172 in dedicated breast clinic).
Hospital anxiety and depression scale anxiety scores at baseline and three weeks: n=361 (208 in one stop clinic and 153 in dedicated breast clinic).
Hospital anxiety and depression scale anxiety scores at baseline and three months: n=378 (220 in one stop clinic and 158 in dedicated breast clinic).
Economic evaluation
A one stop policy cost £32 (95% confidence interval £2 to £62) more per patient; this was largely explained by the additional input of radiologists and pathologists (table 4). The exclusion of excision biopsies slightly increased the difference in mean cost (£34) but substantially reduced its variability (£27 to £41). A sensitivity analysis which assumed that a consultant initially assessed all women in both clinics reduced the difference in mean cost to £29. Assuming that pathology staff were present and not just available throughout the one stop clinic increased the difference to £44, but this fell to £27 if the cytopathologist were to undertake other duties for 75% of this time. Reducing the grade of laboratory staff had little effect.
Table 4.
Mean cost (£) to the NHS of assessment and 12 month follow up of a woman referred for investigation of a breast lump
One stop clinic | Dedicated breast clinic | |
---|---|---|
Staff costs | ||
Assessment: | ||
First clinic visit | ||
surgical | 14.63 | 9.84 |
pathological | 12.34 | N/A |
radiological | 9.90 | N/A |
nursing | 5.83 | 2.96 |
administrative and porterage | 7.38 | 2.92 |
Other assessment clinic visits | 0.73 | 4.39 |
Post-diagnosis clinic visits | 7.94 | 7.02 |
Costs of investigations | ||
Investigations undertaken during assessment: | ||
Mammography | 37.09 | 32.36 |
Ultrasonography | 5.03* | 3.33 |
Fine needle aspiration cytology | 10.42* | 16.34 |
Core biopsy | 2.21 | 2.10 |
Excision biopsy | 31.33 | 33.34 |
Investigations undertaken during 12 month follow up | 7.07 | 5.44 |
Total mean cost | 151.90 | 120.05 |
The cost of a mammogram was £37.94, an ultrasound scan £18.97, aspiration cytology £32.52, a core biopsy (including equipment) £49.25, and day case and inpatient excision biopsies (including pathology costs) £539 and £812.
N/A = not applicable.
In the one stop clinic, costs of an ultrasound scan and aspiration cytology were adjusted (see text).
Discussion
Compared with women attending a dedicated breast clinic, those attending a one stop clinic made fewer visits but at greater cost. Costs saved by reducing the number of prediagnostic visits were more than offset by those of same day radiological and cytopathological reporting. The psychological benefits of attending a one stop clinic were seen only in the short term.
Methodological considerations
The optimum way of delivering a one stop service has not been defined.2–4 Our clinic followed a breast screening model—women with a high index of suspicion of cancer had mammography before clinical assessment. This strategy, used in other one stop clinics,4 may allow for more efficient use of radiologist's time but results in a higher uptake of investigations than in a dedicated breast clinic where referral for investigation follows clinical examination. In the dedicated clinic, ultrasonography was usually requested by the surgeon when mammographic and cytopathological investigations were equivocal. In the one stop clinic, however, the decision to perform ultrasonography was made by the radiologist after reviewing the mammogram, a common practice when assessing women with abnormal screening mammograms.Thus the imbalance in uptake of ultrasonography (which contributed little to the difference in costs) follows from the translation of an investigational strategy from one area of clinical activity to another.14 Costs might have been less if the service had been organised differently, but this is untested. Data collected from 58 patients showed little difference between groups in patient costs. Patient preferences could not be reliably defined as women had experienced only one type of clinic.15
We used a modified Zelen design—consent was sought from patients after randomisation, and only those agreeing to participate were analysed.16 This design was imposed by the need to minimise delay between referral and first appointment and to schedule appointments for busy clinics. To wait to learn whether a woman wished to participate before scheduling her appointment would have resulted in unacceptable delay. To postpone randomisation until clinic attendance, the preferred option, was impossible because the one stop clinic had to start before the dedicated clinic to allow for processing and reporting of investigations and their possible repetition. We did not need to consider the impact of patient transfer on the observed treatment effect because no one switched clinics.16 Some women did not attend, and others could not be identified before assessment; this was more common in the dedicated clinic held in the busy main outpatients department.
Comparison with other studies
Although a similar unsustained reduction in psychological morbidity in women attending a one stop clinic has been reported elsewhere, costs were not measured.2 Concerns have been expressed that same day reporting might compromise diagnostic accuracy. Harcourt et al report two “missed” cancers in one stop clinic patients and one missed cancer in two stop clinic patients,2 and Eltahir et al report four missed cancers during a three year follow up of 1110 one stop referrals.4 Our study was not powered to detect differences in this outcome; the only “missed” cancer occurred in a one stop clinic attender.
Implications for the NHS
Attention is increasingly focused on delays in the patient's cancer journey.17Same day reporting benefits only those women who otherwise would not have been given a diagnosis at their first visit to a dedicated breast clinic; in this trial nearly 50% of women attending a dedicated clinic were given a diagnosis at this visit. We consider that the additional cost to the NHS of this one stop clinic may not be justified in terms of the observed short term reduction in anxiety. Further work is needed to define more precisely the costs and benefits of different strategies to reduce delay. These should be compared with the benefits of further investment in interventions of proved effectiveness.
Figure.
Trial profile
Acknowledgments
We thank the staff at Withington Hospital and the North Western Regional Cancer Registry for their help during this study. We acknowledge the contribution of David Asbury and Luke Readman, who were involved in the study initiation, and of John Coyne and Judith Richardson for their help and advice.
Footnotes
Funding: NHS Executive research and development programme on cancer funded the clinical evaluations.
Competing interests: None declared.
References
- 1.Cancer Guidance Subgroup of the Clinical Outcomes Group. Improving outcomes in breast cancer. The manual. Leeds: NHS Executive; 1996. [Google Scholar]
- 2.Harcourt D, Ambler N, Rumsey N, Cawthorn S. Evaluation of a one-stop breast clinic: a randomised controlled trial. Breast. 1998;7:314–319. [Google Scholar]
- 3.Gui GP, Allum WH, Perry NH, Wells CA, Curling OM, McLean A, et al. One stop diagnosis for symptomatic breast disease. Ann R Coll Surg Engl. 1995;77:24–27. [PMC free article] [PubMed] [Google Scholar]
- 4.Eltahir A, Jibril JA, Squair J, Heys SD, Ah-See AK, Needham G, et al. The accuracy of “one stop” diagnosis for 1110 patients presenting to a symptomatic breast clinic. J R Coll Surg Edinb. 1999;44:226–230. [PubMed] [Google Scholar]
- 5.BASO Breast Specialty Group. The British Association of Surgical Oncology guidelines for surgeons in the management of symptomatic breast disease in the UK (1998 revision) Eur J Surg Oncol. 1998;24:464–476. doi: 10.1016/s0748-7983(98)93104-3. [DOI] [PubMed] [Google Scholar]
- 6.Lucock MP, Morley S, White C, Peake MD. Responses of consecutive patients to reassurance after gastroscopy: results of self administered questionnaire survey. BMJ. 1997;315:572–575. doi: 10.1136/bmj.315.7108.572. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Lowe JB, Balanda KP, Del Mar C, Hawes E. Psychologic distress in women with abnormal findings in mass mammography screening. Cancer. 1999;85:1114–1118. doi: 10.1002/(sici)1097-0142(19990301)85:5<1114::aid-cncr15>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
- 8.Poole K. The emergence of the “waiting game”: a critical examination of the psychosocial issues in diagnosing breast cancer. J Adv Nurs. 1997;25:273–281. doi: 10.1046/j.1365-2648.1997.1997025273.x. [DOI] [PubMed] [Google Scholar]
- 9.Zigmond A, Snaith R. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–370. doi: 10.1111/j.1600-0447.1983.tb09716.x. [DOI] [PubMed] [Google Scholar]
- 10.Speilberger CD. State-trait anxiety inventory for adults. Palo Alto, CA: Consulting Psychologist Press; 1983. [Google Scholar]
- 11.Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319:670–674. doi: 10.1136/bmj.319.7211.670. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Pocock SJ. Clinical trials. A practical approach. Chichester: John Wiley and Sons; 1983. [Google Scholar]
- 13.Senn S, Stevens L, Chaturvedi N. Repeated measures in clinical trials: simple strategies for analysis using summary measures. Stat Med. 2000;19:861–877. doi: 10.1002/(sici)1097-0258(20000330)19:6<861::aid-sim407>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
- 14.Teh W, Wilson AR. The role of ultrasound in breast cancer screening. A consensus statement by the European Group for Breast Cancer Screening. Eur J Cancer. 1998;34:449–450. doi: 10.1016/s0959-8049(97)10066-1. [DOI] [PubMed] [Google Scholar]
- 15.McPherson K, Britton A. The impact of patient treatment preferences on the interpretation of randomised controlled trials. Eur J Cancer. 1999;35:1598–1602. doi: 10.1016/s0959-8049(99)00196-3. [DOI] [PubMed] [Google Scholar]
- 16.Altman DG, Whitehead J, Parmar MKB, Stenning SP, Fayers PM, Machin D. Randomised consent designs in cancer clinical trials. Eur J Cancer. 1995;31A:1934–1944. doi: 10.1016/0959-8049(95)00470-x. [DOI] [PubMed] [Google Scholar]
- 17.Department of Health. The NHS cancer plan. London: Stationery Office; 2000. [Google Scholar]